Free Trial
NASDAQ:HOOK

Hookipa Pharma Q4 2023 Earnings Report

Hookipa Pharma logo
$1.62 +0.10 (+6.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 -0.03 (-1.85%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hookipa Pharma EPS Results

Actual EPS
-$1.10
Consensus EPS
-$2.00
Beat/Miss
Beat by +$0.90
One Year Ago EPS
N/A

Hookipa Pharma Revenue Results

Actual Revenue
$7.41 million
Expected Revenue
$3.60 million
Beat/Miss
Beat by +$3.81 million
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 22, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Hookipa Pharma's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat